Leitner, Brooks P. http://orcid.org/0000-0001-8744-412X
Givechian, Kevin B.
Ospanova, Shyryn
Beisenbayeva, Aray
Politi, Katerina
Perry, Rachel J. http://orcid.org/0000-0003-0748-8064
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99/R00 CA215315, 1P50CA196530, 1P50CA196530)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007205, T32GM007205)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 31 May 2021
Accepted: 16 December 2021
First Online: 27 January 2022
Competing interests
: K.P. is a co-inventor on a patent licensed to Molecular MD for EGFR T790M mutation testing (through MSKCC). K.P. has received Honoraria/Consulting fees from Takeda, NCCN, Novartis, Merck, AstraZeneca, Tocagen, Maverick Therapeutics, Dynamo Therapeutics, and Halda and research support from AstraZeneca, Kolltan, Roche, Boehringer Ingelheim, and Symphogen. R.J.P. has received research support, for a project unrelated to cancer, from AstraZeneca. The remaining authors declare no competing interests.